30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Biotechnology & Medical Research

Prometheus Biosciences Inc (RXDX)

Track

Stock chart
Ticker: RXDX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Marshall Keith W
Chief Financial Officer
1 sale — total 1,084,200 USD
Planned sale 5 Apr 2023
Value US$2,367,119.13 | Price 44.32 | Shares 44,973
Planned sale 15 Mar 2023
Value US$4,828,283.83 | Price 31.45 | Shares 70,833
Proposed sale 8 Mar 2023
Value US$104,405,500.00 | Price 120.70 | Shares 865,000
Sale 8 Mar 2023
Value US$99,120,350.00 | Price 114.59 | Shares 865,000
Planned sale 6 Mar 2023
Value US$1,221,300.00 | Price 122.13 | Shares 10,000
Planned sale 3 Mar 2023
Value US$1,328,880.60 | Price 125.13 | Shares 10,620
Planned sale 1 Mar 2023
Value US$87,682.00 | Price 125.26 | Shares 700
Planned sale 17 Feb 2023
Value US$1,711,368.00 | Price 125.10 | Shares 13,680
Planned sale 16 Feb 2023
Value US$2,996,750.00 | Price 119.87 | Shares 25,000
Planned sale 15 Feb 2023
Value US$2,985,500.00 | Price 119.42 | Shares 25,000
Planned sale 15 Feb 2023
Value US$596,900.00 | Price 119.38 | Shares 5,000
Planned sale 17 Jan 2023
Value US$2,974,750.00 | Price 118.99 | Shares 25,000
Planned sale 17 Jan 2023
Value US$595,000.00 | Price 119.00 | Shares 5,000
Buy 16 Mar 2021
Value US$7,125,000.00 | Price 19.00 | Shares 375,000
Buy 16 Mar 2021
Value US$15,200,000.00 | Price 19.00 | Shares 800,000
Buy 16 Mar 2021
Value US$16,150,000.00 | Price 19.00 | Shares 850,000
Buy 16 Mar 2021
Value US$285,000.00 | Price 19.00 | Shares 15,000
Buy 16 Mar 2021
Value US$9,500.00 | Price 19.00 | Shares 500
Buy 16 Mar 2021
Value US$15,200,000.00 | Price 19.00 | Shares 800,000
Buy 16 Mar 2021
Value US$266,000.00 | Price 19.00 | Shares 14,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2023-04-07 2023-04-05 PlS Planned sale
Marshall Keith W

Chief Financial Officer

Officer
44,973 +6.2%
44.32
US$2,367,119 		44,973 +6.2% 44.32 US$2,367,119
2023-03-17 2023-03-15 PlS Planned sale
0.6
McKenna Mark C.

Chairman, President & CEO

Executive Director
70,833 -36.4%
31.45
US$4,828,284 		70,833 -36.4% 31.45 US$4,828,284
2023-03-08 2023-03-08 PrS Proposed sale
Cedars Sinai Intellectual Property Company

10% Stockholder

Large shareholder
34,528
162.92
US$1,337,787 		34,528 162.92 US$1,337,787
2023-03-08 2023-03-08 S Sale
Cedars Sinai Intellectual Property Co
Large shareholder
865,000 -17.8%
114.59
US$99,120,350 		865,000 -17.8% 114.59 US$99,120,350
2023-03-08 2023-03-06 PlS Planned sale
Marshall Keith W

Chief Financial Officer

Officer
10,000 -50.5%
122.13
US$1,221,300 		10,000 -50.5% 122.13 US$1,221,300
2023-03-03 2023-03-03 PlS Planned sale
0.6
McKenna Mark C.

Chairman, President & CEO

Executive Director
10,620 -16.1%
125.13
US$1,328,881 		10,620 -16.1% 125.13 US$1,328,881
2023-03-03 2023-03-01 PlS Planned sale
0.6
McKenna Mark C.

Chairman, President & CEO

Executive Director
700 -1.3%
125.26
US$87,682 		700 -1.3% 125.26 US$87,682
2023-02-17 2023-02-17 PlS Planned sale
0.6
McKenna Mark C.

Chairman, President & CEO

Executive Director
13,680 -19.9%
125.10
US$1,711,368 		13,680 -19.9% 125.10 US$1,711,368
2023-02-17 2023-02-16 PlS Planned sale
0.6
McKenna Mark C.

Chairman, President & CEO

Executive Director
25,000 -31.2%
119.87
US$2,996,750 		25,000 -31.2% 119.87 US$2,996,750
2023-02-17 2023-02-15 PlS Planned sale
0.6
McKenna Mark C.

Chairman, President & CEO

Executive Director
25,000 -31.2%
119.42
US$2,985,500 		25,000 -31.2% 119.42 US$2,985,500
2023-02-17 2023-02-15 PlS Planned sale
Marshall Keith W

Chief Financial Officer

Officer
5,000 -33.8%
119.38
US$596,900 		5,000 -33.8% 119.38 US$596,900
2023-01-19 2023-01-17 PlS Planned sale
0.6
McKenna Mark C.

Chairman, President & CEO

Executive Director
25,000 -31.2%
118.99
US$2,974,750 		25,000 -31.2% 118.99 US$2,974,750
2023-01-19 2023-01-17 PlS Planned sale
Marshall Keith W

Chief Financial Officer

Officer
5,000 -33.8%
119.00
US$595,000 		5,000 -33.8% 119.00 US$595,000
2021-03-18 2021-03-16 B Purchase
3.8
Cormorant Asset Management, LP
375,000 +20.3%
19.00
US$7,125,000 		375,000 +20.3% 19.00 US$7,125,000
2021-03-17 2021-03-16 B Purchase
Point72 Biotech Private Investments, LLC

Former 10% Owner
800,000 +43.3%
19.00
US$15,200,000 		800,000 +43.3% 19.00 US$15,200,000
2021-03-16 2021-03-16 B Purchase
2.7
PERCEPTIVE ADVISORS LLC
Large shareholder
850,000 +34.5%
19.00
US$16,150,000 		850,000 +34.5% 19.00 US$16,150,000
2021-03-16 2021-03-16 B Purchase
3.1
PAPA JOSEPH C
Non-Executive Director
15,000 +inf%
19.00
US$285,000 		15,000 +inf% 19.00 US$285,000
2021-03-16 2021-03-16 B Purchase
3.3
Adams Helen C.
Non-Executive Director
500 +inf%
19.00
US$9,500 		500 +inf% 19.00 US$9,500
2021-03-16 2021-03-16 B Purchase
2.7
RTW INVESTMENTS, LP
Large shareholder
800,000 +inf%
19.00
US$15,200,000 		800,000 +inf% 19.00 US$15,200,000
2021-03-16 2021-03-16 B Purchase
Stenhouse Mark

Chief Operating Officer

Officer
14,000 +inf%
19.00
US$266,000 		14,000 +inf% 19.00 US$266,000
Explore more

More insider trading research around Prometheus Biosciences Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America